Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILDAS 1
2010-023355-29Phase 2Terminated
- Sponsor
- Papworth Hospital NHS Foundation Trust
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in bronchopulmonary dysplasia (BPD), sponsored by Papworth Hospital NHS Foundation Trust. Primary endpoint: Incidence of high grade dysplasia within the target population. Started Apr 2011; status: terminated.
02
Drugs
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2010-023355-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023355-29.